Study shows different approach after progression in non-small cell lung cancer patients
While more research needed, chemotherapy might not be best treatment
2012-11-15
(Press-News.org) DENVER – Right now, the best known treatment for patients with metastatic non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase gene rearrangements (ALK) or epidermal growth factor receptor mutations (EGFR) is crizotinib or EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, respectively. However, progression inevitably occurs. When it does, having no clear guidelines and/or indications, most patients are treated with chemotherapy. A new study published in the December 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, shows that other approaches to overcome acquired resistance should be considered.
Researchers looked at NSCLC patients with histologically confirmed ALK rearrangements or EGFR mutations who were treated with crizotinib or erlotinib at the University of Colorado Cancer Center between May 2005 and December 2011.
Of the 51 patients whose cancer grew eventually on the targeted drugs, 25 were deemed suitable for local ablative therapy radiotherapy or surgery) to the site of progression, and then continued on the same drug. The use of this strategy prolonged the duration of disease control by the drug by 6.2 months, on top of the median of 9.8 months initial disease control. The benefit was most marked in patients who only experienced isolated growth in the brain – this group had another median 7.1 months of disease control before further growth either in the body and brain.
While the authors point out study limitations and the need for further research, they say their experience suggests that when NSCLC patients with EGFR mutations or ALK rearrangements "progress on erlotinib or crizotinib, respectively, and the progression occurs in only a limited number of sites (oligoprogressive disease) it may be reasonable to consider LAT to the sites of progression and continuation of the TKI."
###
The lead author of this work is IASLC member Dr. Andrew Weickhardt. Co-authors include IASLC members Dr. Paul Bunn, Dr. Dara Aisner, Dr. Laurie Gaspar, Dr. Robert Doebele and Dr. Ross Camidge.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association's membership includes more than 3,500 lung cancer specialists in 80 countries. To learn more about IASLC please visit www.iaslc.org.
ELSE PRESS RELEASES FROM THIS DATE:
2012-11-15
BOSTON – Mesenchymal stem cells (MSCs), are a newly emerging cellular therapy being tested in approximately 250 clinical trials worldwide to help repair damaged tissues, such as injured heart muscle following a heart attack. The problem is that when culture-expanded MSCs are injected into the circulation, they have trouble gaining access to the inflamed tissues—exactly where their help is needed.
Now, research led by investigators at Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women's Hospital (BWH) reveals new insights into how MSCs "traffic" from the ...
2012-11-15
It's a popularly held belief that individuals with an autism spectrum disorder (ASD) gravitate toward STEM majors in college (science, technology, engineering mathematics).
A new study, co-authored by Paul Shattuck, PhD, assistant professor at the Brown School at Washington University in St. Louis, confirms that view yet finds that young adults with an ASD also have one of the lowest overall college enrollment rates.
The study, "STEM Participation Among College Students with an Autism Spectrum Disorder," was published online Nov. 1 in the Journal of Autism and Developmental ...
2012-11-15
Putnam Valley, NY. (Nov. 15, 2012) – Researchers in Taiwan have developed a "safe, feasible and robust co-culture system" supplied by human umbilical cord mensenchymal stem cells (HUCMSCs) to feed the sustained culture used for human embryonic stem cell (hESC) expansion prior to cell transplantation. The co-culture, said the researchers, "appears to eliminate the most feared characteristic of transplanted hESCs," which is their propensity to form tumors.
The study, published in the current issue of CELL TRANSPLANTATION, is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/. ...
2012-11-15
CHAMPAIGN, Ill. — They're soft, biocompatible, about 7 millimeters long – and, incredibly, able to walk by themselves. Miniature "bio-bots" developed at the University of Illinois are making tracks in synthetic biology.
Designing non-electronic biological machines has been a riddle that scientists at the interface of biology and engineering have struggled to solve. The walking bio-bots demonstrate the Illinois team's ability to forward-engineer functional machines using only hydrogel, heart cells and a 3-D printer.
With an altered design, the bio-bots could be customized ...
2012-11-15
The recent storms that have battered settlements on the east coast of America may have been much more frequent in the region 450 million years ago, according to scientists.
New research pinpointing the positions of the Equator and the landmasses of the USA, Canada and Greenland, during the Ordovician Period 450 million years ago, indicates that the equator ran down the western side of North America with a hurricane belt to the east.
The hurricane belt would have affected an area covering modern day New York State, New Jersey and most of the eastern seaboard of the ...
2012-11-15
Putnam Valley, NY. (Nov. 15, 2012) – Two studies published in the current issue of Cell Transplantation (21:7), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, investigate the role of oxygen in cell transplantation.
In a study carried out at Baylor University, researchers concerned about the poor efficacy of islet cell transplantation during pancreas preservation and islet isolation have found that low temperatures can prevent hypoxia (low oxygen) that can damage islet cells. In a second study, Brazilian researchers found that neural cells ...
2012-11-15
ALBUQUERQUE, N.M. — Researchers at Sandia National Laboratories and the University of New Mexico are comparing supercomputer simulations of blast waves on the brain with clinical studies of veterans suffering from mild traumatic brain injuries (TBIs) to help improve helmet designs.
Paul Taylor and John Ludwigsen of Sandia's Terminal Ballistics Technology Department and Corey Ford, a neurologist at UNM's Health Sciences Center, are in the final year of a four-year study of mild TBI funded by the Office of Naval Research.
The team hopes to identify threshold levels of ...
2012-11-15
Livermore, Calif. -- Lawrence Livermore National Laboratory (LLNL) researchers have used the Stack Trace Analysis Tool (STAT), a highly scalable, lightweight tool to debug a program running more than one million MPI processes on the IBM Blue Gene/Q (BGQ)-based Sequoia supercomputer.
The debugging tool is a significant milestone in LLNL's multi-year collaboration with the University of Wisconsin (UW), Madison and the University of New Mexico (UNM) to ensure supercomputers run more efficiently.
Playing a significant role in scaling up the Sequoia supercomputer, STAT, ...
2012-11-15
CHAMPAIGN, Ill. — Frontline employees will commit to improving their organization if they perceive a high degree of autonomy in their jobs and trust their leaders, says research from University of Illinois business professors.
According to a soon-to-be-published study by Gopesh Anand and Dilip Chhajed, professors of business administration at Illinois, a flexible work environment plays a significant role in increasing employee commitment to continuous improvement initiatives.
"Continuous improvement initiatives are typically bundled with employee empowerment techniques," ...
2012-11-15
Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin©), Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology.
The researchers conducted this study because older women who are at higher risk of decreased heart function, were often excluded from randomized clinical trials of trastuzumab, which is used to treat breast tumors that over-express human epidermal growth factor receptor-2 (HER-2). ...
LAST 30 PRESS RELEASES:
[Press-News.org] Study shows different approach after progression in non-small cell lung cancer patients
While more research needed, chemotherapy might not be best treatment
